Ratio Therapeutics Appoints Marcel Reichen as Chief Strategy Officer
Ratio Therapeutics announced on November 4, 2025, the appointment of Marcel Reichen, Ph.D., MBA, as Chief Strategy Officer, not Chief Scientific Officer12358.
Dr. Reichen brings over a decade of international leadership in the pharmaceutical and radioligand therapy (RLT) sectors, including strategic roles at Novartis, Advanced Accelerator Applications, and Bayer123.
His expertise includes driving value creation, strategic planning, and business development, with a focus on radioligand therapy and oncology123.
At Ratio Therapeutics, Dr. Reichen will guide the company’s strategic direction as it expands collaborations and advances its radiopharmaceutical pipeline123.
Ratio Therapeutics is preparing to initiate a Phase 1/2 clinical trial for a FAP-targeted radiotherapeutic for patients with relapsed or refractory soft tissue sarcoma, and is advancing other programs including [Lu-177]-RTX2358 and a Granzyme B-targeted PET imaging agent12.
Dr. Reichen holds a Ph.D. in Biochemical Engineering from UCL, an M.Sc. in Mechanical Engineering from ETH Zurich, and an MBA from the University of St. Gallen123.
This hiring is viewed as pivotal for Ratio as it seeks to strengthen its leadership in precision oncology and radiopharmaceutical innovation123.
Sources:
1. https://www.prnewswire.com/news-releases/ratio-therapeutics-announces-the-appointment-of-marcel-reichen-as-chief-strategy-officer-302603416.html
2. https://www.biospace.com/press-releases/ratio-therapeutics-announces-the-appointment-of-marcel-reichen-as-chief-strategy-officer
3. https://www.pharmanow.live/latest-news/ratio-appoints-marcel-reichen-strategy
5. https://app.fundz.net/executives/ratio-therapeutics-hired-ec1b